Compare Lucid Group Inc (LCID) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs ResMed Inc. — how do they compare? Lucid Group Inc trades at $6.65 (market cap $2.64B), while ResMed Inc. trades at $222.1 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 12.4× Lucid Group Inc's market cap, and ResMed Inc. pays a 1.17% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals.
| LCID | RMD | |
|---|---|---|
Market Cap | $2.64B | $32.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.77 | $293.73 |
52-Week Low | $4.62 | $182.82 |
Enterprise Value | $5.54B | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $6.61, down 6.11% amid ongoing operational challenges. The stock shows bearish technical signals with negative moving averages and faces fundamental headwinds including consistent quarterly losses, negative profit margins, and substantial cash burn. Recent news highlights an operational reset targeting $1.4 billion in cash improvements and delays to the affordable Cosmos EV launch to 2027.
The outlook remains challenging with deep losses and cash burn overshadowing revenue growth. Analyst consensus is cautious with 67% hold ratings, though the $10.50 price target suggests potential upside. Key risks include execution of turnaround plans, intense EV competition, and funding needs. The stock's direction hinges on successful cost reductions and future product execution.
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
